Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients

Bone Marrow Transplantation volume 27, pages 829–835 (2001)Cite this article

Abstract

Reinforced chemotherapy based on a double high-dose consolidation regimen could be a different way to enhance in vivo purging prior to autologous stem cell transplantation (auto-SCT) in acute myeloid leukemia (AML). We investigated the impact on outcome of auto-SCT after two different strategies of early intensification performed after an identical induction regimen in adult patients with AML. Between January 1993 and December 1998, 140 consecutive AML patients were enrolled in a program consisting of an identical anthracycline-based induction (ICE) and two different consolidation regimens: one cycle, cytarabine-based (single-NOVIA: 91 patients); two cycles, fludarabine-based (double-FLAN: 49 patients). Seventy out of 91 patients received single-NOVIA consolidation: 60 underwent a transplantation procedure (allogeneic bone marrow transplantation (allo-BMT):16 patients; auto-SCT: 44). Thirty-five out of 49 patients received double-FLAN consolidation: 31 underwent a transplantation procedure (allo-BMT: 10; auto-SCT: 21). The double consolidation regimen was well-tolerated with only minor side-effects. Median follow-up observation time for surviving patients was 38 months (range, 17–71) for the double-FLAN consolidation group and 70 months (range: 48–93) for the single-NOVIA consolidation group. Among the patients who received auto-SCT, the double consolidation strategy produced a superior disease-free survival curve at 36 months (78.6% (95%CI: 59.4–97.8) vs 47.7% (95%CI: 33–62.4)) compared with the single-NOVIA group. This difference was confirmed when the patients were analyzed for intention to treat (P = 0.04). In addition, the double-FLAN consolidation group showed a superior overall survival and lower relapse rate (P = 0.02). We conclude that the double-FLAN reinforcement strategy is safe and enhances the clinical impact of auto-SCT for AML patients in first complete remission. It may provide specific clinical benefit for patients undergoing auto-SCT. Bone Marrow Transplantation (2001) 27, 829–835.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Zittoun RA, Mandelli F, Willemze R et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia New Engl J Med 1995 332: 217–233

    Article  CAS  PubMed  Google Scholar 

  2. Mayer RJ, Davis RB, Schiffer CA et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia New Engl J Med 1994 331: 896–903

    Article  CAS  PubMed  Google Scholar 

  3. Gorin NC, Dicke K, Lowenberg B et al. High dose therapy for acute myelocytic leukemia treatment strategy: what is the choice? Ann Oncol 1995 4: (Suppl. 1) 59–80

    Article  Google Scholar 

  4. Lowenberg B, Verdonck LJ, Dekker W et al. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study J Clin Oncol 1994 8: 287–294

    Article  Google Scholar 

  5. Burnett AK, Goldstone AH, Stevens RMF et al. Randomized comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: results of MRC AML 10 trial Lancet 1998 351: 700–709

    Article  CAS  PubMed  Google Scholar 

  6. Visani G, Lemoli RM, Tosi P et al. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells Bone Marrow Transplant 1999 24: 467–472

    Article  CAS  PubMed  Google Scholar 

  7. Mehta J, Powles R, Singhal S et al. Peripheral blood stem cell transplantation may result in increased relapse of acute myeloid leukemia due to reinfusion of a higher number of malignant cells Bone Marrow Transplant 1995 15: 652–653

    CAS  PubMed  Google Scholar 

  8. Laporte JP, Gorin NC, Feuchtenbaum J et al. Relapse after autografting with peripheral blood stem cells Lancet 1997 2: 1993–1999

    Google Scholar 

  9. Schiller G, Lee M, Miller T et al. Transplantation of autologous peripheral blood progenitor cells procured after high dose cytarabine based consolidation chemotherapy for adults with acute myelogenous leukemia in first remission Leukemia 1997 11: 1533–1539

    Article  CAS  PubMed  Google Scholar 

  10. Schlenk RF, Dohner H, Pforsich M et al. Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukemia following early consolidation therapy with granulocyte colony-stimulating factor-supported high-dose cytarabine and mitoxantrone Br J Haematol 1997 99: 386–393

    Article  CAS  PubMed  Google Scholar 

  11. Martin C, Torres A, Leon A et al. Autologous peripheral blood stem cell transplantation mobilized with G-CSF in AML in first complete remission. Role of intensification therapy in outcome Bone Marrow Transplant 1998 21: 375–382

    Article  CAS  PubMed  Google Scholar 

  12. Visani G, Tosi P, Zinzani PL et al. FLAG (Fludarabine + high dose ara-C + G-CSF): an effective and tolerable protocolfor the treatment of ‘poor risk’ acute myeloid leukemias Leukemia 1994 8: 1842–1846

    CAS  PubMed  Google Scholar 

  13. Estey E, Thall P, Andreeff M et al. Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor J Clin Oncol, 1994 12: 671–678

    Article  CAS  PubMed  Google Scholar 

  14. Clavio M, Carrara P, Miglino M et al. High efficacy of fludarabine containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia Haematologica 1996 81: 513–520

    CAS  PubMed  Google Scholar 

  15. Bennet JM, Catovsky DM, Daniel MT et al. Proposals for the classification of acute leukemias Br J Haematol, 1977 33: 451–458

    Article  Google Scholar 

  16. Cheson BD, Cassileth PA, Head DR et al. Report of National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia J Clin Oncol 1990 8: 813–819

    Article  CAS  PubMed  Google Scholar 

  17. Lemoli RM, Visani G, Leopardi G et al. Autologous transplantation of chemotherapy-purged PBSC collection from high-risk leukemia patients: a pilot study Bone Marrow Transplant, 1999 23: 235–241

    Article  CAS  PubMed  Google Scholar 

  18. Carella AM, Dejana A, Lerma E et al. In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy related acute myelogenous leukemia Br J Haematol 1996 95: 127–130

    Article  CAS  PubMed  Google Scholar 

  19. Visani G, Lemoli RM, Tosi P et al. Fludarabine containing-regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukemia patients Br J Haematol 1999 105: 775–779

    Article  CAS  PubMed  Google Scholar 

  20. Miggiano MC, Gherlinzoni F, Rosti G et al. Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia Leukemia 1996 10: 402–409

    CAS  PubMed  Google Scholar 

  21. Lemoli RM, Fortuna A, Motta MR et al. Concomitant mobilization of plasma cells and haemopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells Blood 1996 87: 1625–1634

    CAS  PubMed  Google Scholar 

  22. Testoni N, Lemoli RM, Martinelli G et al. Autologous PBSCT in acute myeloblastic leukemia and MDS. Evaluation of tumor cell contamination of leukapheresis by cytogenetic and molecular methods Bone Marrow Transplant 1998 22: 1065–1070

    Article  CAS  PubMed  Google Scholar 

  23. Sanz MA, de la Rubia J, Sanz G et al. Busulphan and cyclophosphamide followed by complete remission: a report from a single institution J Clin Oncol 1993 11: 1661–1667

    Article  CAS  PubMed  Google Scholar 

  24. Kaplan EL, Meier P . Non-parametric estimation from incomplete observation J Am Stat Assoc 1958 53: 457–481

    Article  Google Scholar 

  25. Peto R, Pike MC, Armitage NE . Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Part II. Analysis and examples Br J Cancer 1977 35: 1–39

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Cassileth PA, Andersen J, Lazarus HM et al. Autologous bone marrow transplantation in acute myeloid leukemia in first remission J Clin Oncol 1993 11: 314–319

    Article  CAS  PubMed  Google Scholar 

  27. Demirer T, Petersen FB, Bensinger WI et al. Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia Bone Marrow Transplant 1996 18: 29–34

    CAS  PubMed  Google Scholar 

  28. Reiffers J, Korbling M, Labopin M et al. Autologous blood stem cell transplantation versus autologous bone marrow transplantation for acute myeloid leukemia in first complete remission J Cell Cloning 1992 7: (Suppl. 1) 111–113

    Article  Google Scholar 

  29. Labopin M, Gorin NC, Ringden O et al. Autologous bone marrow transplantation in 2502 patients with acute leukemia in Europe: a retrospective study Leukemia 1992 6: (Suppl. 4) 95–99

    PubMed  Google Scholar 

  30. Korbling M, Hunstein W, Fliedner TM et al. Disease-free survival after autologous bone marrow transplantation in patients with acute myelogenous leukemia Blood 1989 74: 1898–1904

    CAS  PubMed  Google Scholar 

  31. McMillan AK, Goldstone AH, Linch DC et al. High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia Blood 1990 76: 480–488

    CAS  PubMed  Google Scholar 

  32. To LB, Roberts MM, Haylock DN et al. Comparison of hematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants Bone Marrow Transplant 1992 9: 277–284

    CAS  PubMed  Google Scholar 

  33. Visani G, Di Nota A, Tosi P et al. Cryopreserved autologous bone marrow transplantation in patients with acute nonlymphoid leukemia: chemotherapy before harvesting is the main factor in delaying the hematological recovery Cryobiology 1990 27: 103–106

    Article  CAS  PubMed  Google Scholar 

  34. Motta RM, Mangianti S, Rizzi S et al. Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies Exp Hematol 1997 25: 1261–1269

    CAS  PubMed  Google Scholar 

  35. Korbling M, Fliedner TM, Holle R et al. Autologous blood stem cell (ABSCT) versus purged bone marrow transplantation (ABMT) in standard risk AML: influence of source and cell composition of the autograft on haemopoietic reconstitution and disease-free survival Bone Marrow Transplant 1991 7: 343–349

    CAS  PubMed  Google Scholar 

  36. Gondo H, Harada M, Miyamoto T et al. Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia Bone Marrow Transplant 1997 20: 821–826

    Article  CAS  PubMed  Google Scholar 

  37. Vellenga E, van Putten WL, Bogaerts MA et al. Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia Bone Marrow Transplant 1999 23: 343–349

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported in part by MURST ex 40% (S Tura) and MURST ex 60% (S Tura).

Author information

Authors and Affiliations

  1. Institute of Hematology and Medical Oncology ‘L and A Seragnoli’, Bologna University, Bologna, Italy

    G Visani, RM Lemoli, A Isidori, PP Piccaluga, G Martinelli, M Malagola, F Bonifazi, MR Motta, S Rizzi, S Castellani & S Tura

  2. Division of Hematology, Arcispedale Reggio Emilia, Italy

    L Gugliotta & A Bonini

Authors
  1. G Visani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. RM Lemoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Isidori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. PP Piccaluga
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G Martinelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Malagola
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L Gugliotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Bonini
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F Bonifazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. MR Motta
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S Rizzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. S Castellani
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. S Tura
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Visani, G., Lemoli, R., Isidori, A. et al. Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients. Bone Marrow Transplant 27, 829–835 (2001). https://doi.org/10.1038/sj.bmt.1703003

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703003

Keywords

This article is cited by

Search

Advanced search

Quick links